Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company.
Galapagos NV (GLPG:NASDAQ; GLPG:BSE) ADR shares opened up over 18% higher today after announcing that it has entered into a 10-year global research and development collaboration with Gilead Sciences Inc. (GILD:NASDAQ). The report advised that through the agreement Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
As structured, Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead. Galapagos plans to use the proceeds to expand and accelerate its R&D programs, and Gilead will receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe. The two companies also agreed to amend certain terms in the agreement governing filgotinib, the candidate being advanced for rheumatoid arthritis and other inflammatory diseases to provide a broader commercialization role for Galapagos in Europe.
The report claims that the collaboration will allow for closer scientific partnership between the companies. Gilead will have access to Galapagos' established research base, which includes more than 500 scientists, and to Galapagos' unique platform that utilizes disease-related, human primary cell-based assays to discover and verify novel drug targets.
Based upon the formula outlined in the news release, Gilead's equity investment will consist of a subscription for new Galapagos shares at a price of EUR 140.59 per share representing a 20% premium to Galapagos' 30-day, volume-weighted average price. This will increase Gilead's ownership in Galapagos from approximately 12.3% to 22% of the issued and outstanding shares. The transaction is expected to close late in Q3/19 subject to shareholder and U.S. and E.U. regulatory approvals.
Galapagos describes itself as a clinical-stage biotechnology company specializing in discovering and developing small molecule medicines with novel modes of action. Its pipeline comprises discovery programs through Phase 3 programs in inflammation, fibrosis and other indications. The firm states its mission is to develop first-in-class medicines based on the discovery of novel proteins ("targets") that play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis.
Gilead, headquartered in Foster City, Calif., is a research-based biopharmaceutical company with operations in more than 35 countries. The company focuses on four primary therapeutic areas: HIV, liver disease, oncology and inflammation.
Galapagos shares opened up higher today at $172.33 (+$26.58, +18.24%) over Friday's close of $145.75/share. The company traded over one million shares in the first hour of trading and hit a 52-week intraday high price of $172.99 earlier in the day. Gilead shares are presently trading up at $68.04 (+$1.78, +2.69%) over the prior day's close.
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.